Cyteph was last night awarded $1.5m from the Australian Federal Government’s Medical Research Future Fund – via a clinical CUREator grant – to advance the treatment landscape for an aggressive form of brain cancer.
This grant signals an official launch milestone for the Company, supporting its imminent plan to conduct a phase 1 clinical trial for its lead candidate CYT-101 in recurrent glioblastoma multiforme (GBM) patients.
Under the guidance of QIMR Berghofer’s Professor Rajiv Khanna, the goal is to develop allogeneic or ‘off-the-shelf’ T cell therapies and a dual-targeting CAR T platform to rapidly advance the treatment of solid tumours.
